Company Profile

Isoplexis Inc (AKA:Isoplexis Corporation)
Profile last edited on: 10/10/2022            CAGE: 6XCE6            UEI: FRM2JMLMGJK1

Single-cell, protein response analysis platform.
Year Founded
2012
1st Award Year
2015
Latest Award
2021
Program Status
Active
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

35 NE Industrial Road
Branford, CT 06405
   (203) 233-9700
   info@isoplexis.com
   www.isoplexis.com
Multiple Locations:   
Congressional District:   03
County:   New Haven

Public Profile

Previously located in Wilmington DE and now relocated to Brandford. CT, IsoPlexis (NASDAQ:ISO) - an active SBIR player for some time - is a life sciences company developing a diagnostic platform to measure cellular immune responses in patients. With research areas emcompassing cell engineering & therapy, checkpoint & combination Immunotherapies, vaccines & immunology research, Iinflammatory & autoimmune disease and solid tumor & oncology, the company’s single-cell immune biomarkers are used to detect cellular responses at the single cell level to help determine individual therapeutic response. Originally spun out of Yale, the firm is developing a diagnostic platform to accelerate immunology research and therapeutic development assessing safety and efficacy of therapeutics, and monitoring disease progression - effectively enabling improved therapeutic development and informing physician decisions. Mostly focused to highly sensitive, multiplexed single-cell analysis tools for the life sciences, the firm's specialties include 'secretomic' analysis (in situ proteomics) for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research (including iPS), and oncology (including diagnostic tumor progression).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
5-9

Awards Distribution by Agency

Key People / Management

  Rong Fan -- Co-Founder and Chair

  Sean Mackay -- Chief Executive Officer & Co-Founder + DireCTOr

  Michael Aiello -- VP of Finance

  Kara Brower -- Co-Founder

  Carrie Carter -- Chief of Staff

  Lynne Frick -- VP of Business Development

  Timothy S McConnell

  Peter Siesel -- Chief Commercial Officer

  Verna Siu -- VP of Sales Operations and BD

  Maithreyan Srinivasan -- Consulting Chief Technology Officer

  John Strahley -- Chief Financial Officer

  Peter Tsiomplikas -- Director of Automation

  Rui Zheng

  Jing Zhou -- VP Immunology

SBIR firms in the news